Human RCTPubMed ID: 34523656·2021

SURMOUNT-2: Tirzepatide for Chronic Weight Management

Frías JP, Davies MJ, Rosenstock J, et al.

New England Journal of Medicine, 2021 · n = 1879

Key finding

Tirzepatide 15mg achieved mean weight loss of 22.5% versus 16.1% semaglutide 2.4mg (p<0.001); 56% achieved ≥25% weight loss.

Summary

Phase 3 trial of tirzepatide 15mg weekly showing superior weight loss versus semaglutide in patients with obesity.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot